PAR 1.67% 30.5¢ paradigm biopharmaceuticals limited..

Share price performance, page-13

  1. 4,227 Posts.
    lightbulb Created with Sketch. 6702
    Yes agreed, I think the jury is out, there are some trials that are taking place or being constructed, but a lot more needs to be done. There are a number of issues and while not exhaustive, some issues include the below. Certainly not comparable to the hard and clinical evidence we are witnessing with iPPS and it's respective safety profile and benefits to date:



    • Can be additive - "It has been shown that one in every eleven individuals (9% of individuals) consuming cannabis will become dependent on the drug". 1

    • In terms of patients, it is usually dose dependant, it's not a set formula like how iPPS works. Thus each patient will have to have their dosage theoretically tailored for them. Results will vary, there are a number of factors that could make it more or less effective. (eg how much food, what you have consumed recently, how it mixes etc etc.

    • Longer term usage specifically for OA is not known, "Even though pain management is one of the most common reasons people use medical marijuana in the U.S., there is limited evidence that marijuana works to treat most types of chronic pain." 2

    • More research via clinical trials needs to be done

    • Some variants can have effects on the brain (make you high etc), there could be increased risk of schizophrenia or other psychotic illnesses, again longer term studies need to test this.

    • Route of administration, again more works need to be done, smoking it can have carcinogenic properties, finally there is an amount of ash you are breathing in.


    Other issues involved, will be years before they can (if they are ever successful) in tailoring something in this area for OA, even then not sure it will line up to iPPS in any meaningful way.

    Just to me, it sounds more along the lines of opioids and temporary pain management, then blanket pain suppression as opposed to the well, "Multi Modal" pathways as recently mentioned.



    DYOR as usual


    REFERENCES
    1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053383/
    2) https://www.cdc.gov/marijuana/health-effects.html
    Last edited by Mozzarc: 30/11/20
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
30.5¢
Change
0.005(1.67%)
Mkt cap ! $106.6M
Open High Low Value Volume
30.5¢ 31.5¢ 29.5¢ $152.7K 501.9K

Buyers (Bids)

No. Vol. Price($)
2 16864 30.5¢
 

Sellers (Offers)

Price($) Vol. No.
31.5¢ 20426 2
View Market Depth
Last trade - 16.10pm 17/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.